Cassava Sciences Management
Management criteria checks 3/4
Cassava Sciences' CEO is Rick Barry, appointed in Sep 2024, has a tenure of less than a year. directly owns 0.98% of the company’s shares, worth $1.10M. The average tenure of the management team and the board of directors is 2.1 years and 6.8 years respectively.
Key information
Rick Barry
Chief executive officer
US$546.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 1.0% |
| Management average tenure | 2.1yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Cassava Q3 Earnings Review: It Feels Like The End May Be Nigh
Nov 07Cassava Sciences: Turning The Corner Into A Brick Wall
Jul 24Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28CEO
Rick Barry (65 yo)
less than a year
Tenure
US$546,155
Compensation
Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$546.16k | 0.98% $ 1.1m | |
| Chief Financial Officer | 6.2yrs | US$2.99m | 0.024% $ 27.0k | |
| Senior VP | 2.2yrs | US$1.27m | 0% $ 0 | |
| Chief Medical Officer | 3.9yrs | US$2.97m | 0% $ 0 | |
| Senior Vice President of Technology | no data | no data | no data | |
| Senior Vice President of Technical Operations | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.1yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Clinical Development Officer | less than a year | no data | no data |
2.1yrs
Average Tenure
62.5yo
Average Age
Experienced Management: SAVA's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.5yrs | US$546.16k | 0.98% $ 1.1m | |
| Independent Director | 17yrs | US$438.42k | 0.0025% $ 2.8k | |
| Independent Director | 26.5yrs | US$438.42k | 0.017% $ 19.4k | |
| Member of Scientific Advisory Board | 10.2yrs | US$558.31k | no data | |
| Independent Director | 21.8yrs | US$546.16k | 0.026% $ 29.9k | |
| Independent Chairman | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 | |
| Independent Director | less than a year | US$474.50k | 0% $ 0 |
6.8yrs
Average Tenure
68.5yo
Average Age
Experienced Board: SAVA's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cassava Sciences, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Fraser | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Charles Duncan | Cantor Fitzgerald & Co. |